Search

Author/Creator Hodi, F S

1. 1135PDCharacterization of the immune tumor microenvironment (TME) to inform personalized medicine with immuno-oncology (IO) combinations. (23rd October 2018)

Authors:
Luke, J J; Edwards, R; Hedvat, C; Pandya, D; Ely, S; Meier, R; McDonald, D; Harbison, C T; Baxi, V; Lee, G; Szabo, P; Garcia, T; Bao, R; Reilly, T P; Jaffee, E; Hodi, F S
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 1248PDEfficacy of pembrolizumab (Pembro) in patients (Pts) with advanced melanoma with stable brain metastases (BM) at baseline: A pooled retrospective analysis. (23rd October 2018)

Authors:
Hamid, O; Ribas, A; Daud, A; Butler, M O; Carlino, M S; Hwu, W-J; Long, G V; Ancell, K; Hodi, F S; Khushalani, N I; Blank, C U; Loquai, C; Lin, J; Diede, S J; Robert, C
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 1302TiPCA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti–LAG-3) in combination with nivolumab (anti–PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma. (23rd October 2018)

Authors:
Lipson, E J; Long, G V; Tawbi, H; Schadendorf, D; Atkinson, V G; Maurer, M; Simonsen, K L; Harbison, C; Hodi, F S
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. (31st January 2019)

Authors:
Hamid, O; Robert, C; Daud, A; Hodi, F S; Hwu, W J; Kefford, R; Wolchok, J D; Hersey, P; Joseph, R; Weber, J S; Dronca, R; Mitchell, T C; Patnaik, A; Zarour, H M; Joshua, A M; Zhao, Q; Jensen, E; Ahsan, S; Ibrahim, N; Ribas, A
Journal:
Annals of oncology
Issue:
Volume 30:Number 4(2019)
Page Start:
582
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. LBA44Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067). (23rd October 2018)

Authors:
Hodi, F S; Chiarion-Sileni, V; Gonzalez, R; Grob, J J; Rutkowski, P; Cowey, C L; Lao, C; Schadendorf, D; Wagstaff, J; Dummer, R; Ferrucci, P F; Smylie, M; Hill, A G; Hogg, D; Marquez-Rodas, I; Jiang, J; Rizzo, J; Larkin, J; Wolchok, J
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response. (23rd January 2019)

Authors:
Stein, J E; Soni, A; Danilova, L; Cottrell, T R; Gajewski, T F; Hodi, F S; Bhatia, S; Urba, W J; Sharfman, W H; Wind-Rotolo, M; Edwards, R; Lipson, E J; Taube, J M
Journal:
Annals of oncology
Issue:
Volume 30:Number 4(2019)
Page Start:
589
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search